Context Therapeutics Inc.(CNTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CNTX Context Therapeutics Inc.

Market Closed 06-26 16:00:00 EDT

0.5800

+0.0200

+3.57%

盘后0.5896

+0.0096+1.66%

19:55 EDT

High0.6179	Low0.5600	Vol14.82M
Open0.5650	D1 Closing0.5600	Amplitude10.34%
Mkt Cap53.29M	Tradable Cap23.13M	Total Shares91.88M
T/O8.66M	T/O Rate37.16%	Tradable Shares39.87M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CNTX","market":"US","secType":"STK","nameCN":"Context Therapeutics Inc.","latestPrice":0.58,"timestamp":1782504000000,"preClose":0.56,"halted":0,"volume":14816397,"hourTrading":{"tag":"盘后","latestPrice":0.5896,"preClose":0.58,"latestTime":"19:55 EDT","volume":2323301,"amount":1347621.7192,"timestamp":1782518115688,"change":0.0096,"changeRate":0.016552,"amplitude":0.08},"delay":0,"changeRate":0.035714285714285546,"floatShares":39871400,"shares":91879177,"eps":-0.422618,"marketStatus":"Market Closed","change":0.02,"latestTime":"06-26 16:00:00 EDT","open":0.565,"high":0.6179,"low":0.56,"amount":8657543.7645546,"amplitude":0.103393,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.422618,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782720000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1634702400000,"exchange":"NASDAQ","adjPreClose":0.56,"preHourTrading":{"tag":"盘前","latestPrice":0.5712,"preClose":0.56,"latestTime":"09:25 EDT","volume":11648,"amount":6515.80384,"timestamp":1782480358735,"change":0.0112,"changeRate":0.02,"amplitude":0.037857},"postHourTrading":{"tag":"盘后","latestPrice":0.5896,"preClose":0.58,"latestTime":"19:55 EDT","volume":2323301,"amount":1347621.7192,"timestamp":1782518115688,"change":0.0096,"changeRate":0.016552,"amplitude":0.08},"volumeRatio":4.597659557618562},"requestUrl":"/m/hq/s/CNTX/wiki","defaultTab":"wiki","newsList":[{"id":"2646360874","title":"Context Therapeutics Shareholders Approve Increase in Authorized Common Shares to 300 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2646360874","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646360874?lang=en_us&edition=fundamental","pubTime":"2026-06-27 04:08","pubTimestamp":1782504522,"startTime":"0","endTime":"0","summary":"Context Therapeutics shareholders approve increase in authorized common shares to 300 millionContext Therapeutics held its annual shareholder meeting on June 24, 2026.Shareholders backed an amendment ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL72M8XF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643635200","title":"Context Therapeutics selloff brings buying opportunity, says JonesResearch","url":"https://stock-news.laohu8.com/highlight/detail?id=2643635200","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643635200?lang=en_us&edition=fundamental","pubTime":"2026-06-16 01:35","pubTimestamp":1781544949,"startTime":"0","endTime":"0","summary":"JonesResearch views today’s selloff in shares of Context Therapeutics (CNTX) as a buying opportunity. Context’s Phase I study update of CTIM-76 in ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/context-therapeutics-selloff-brings-buying-opportunity-says-jonesresearch-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/context-therapeutics-selloff-brings-buying-opportunity-says-jonesresearch-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","CNTX","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643220743","title":"Analysts Offer Insights on Healthcare Companies: Dyadic International (DYAI) and Context Therapeutics (CNTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643220743","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643220743?lang=en_us&edition=fundamental","pubTime":"2026-06-16 00:50","pubTimestamp":1781542219,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dyadic International (DYAI) and Context Therapeutics...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dyadic-international-dyai-and-context-therapeutics-cntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dyadic-international-dyai-and-context-therapeutics-cntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4139","BK4588","LU0029874061.USD","LU0128526141.USD","BK4585","BK4137","CNTX","XLV","DYAI","HCSG","XBI","BK4581","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643620767","title":"Context stock reaction ‘overdone’ after CTIM-76 data, says H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2643620767","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643620767?lang=en_us&edition=fundamental","pubTime":"2026-06-16 00:30","pubTimestamp":1781541038,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Emily Bodnar tells investors in a research note that Context Therapeutics (CNTX)’ initial CTIM-76 data in heavily pretreate...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/context-stock-reaction-overdone-after-ctim-76-data-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/context-stock-reaction-overdone-after-ctim-76-data-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643092742","title":"Context Therapeutics Highlights Positive CTIM-76 Phase 1 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2643092742","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643092742?lang=en_us&edition=fundamental","pubTime":"2026-06-15 21:52","pubTimestamp":1781531522,"startTime":"0","endTime":"0","summary":"An announcement from Context Therapeutics ( ($CNTX) ) is now available. On June 15, 2026, Context Therapeutics posted an updated corporate presenta...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-highlights-positive-ctim-76-phase-1-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-highlights-positive-ctim-76-phase-1-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","LENZ","CNTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643164277","title":"Context Therapeutics announces ‘positive’ results from Phase 1 CTIM-76 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2643164277","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643164277?lang=en_us&edition=fundamental","pubTime":"2026-06-15 18:37","pubTimestamp":1781519841,"startTime":"0","endTime":"0","summary":"Context Therapeutics (CNTX) announced positive interim Phase 1 clinical data for its CLDN6 x CD3 T cell engaging bispecific antibody, CTIM-76, in a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/context-therapeutics-announces-positive-results-from-phase-1-ctim-76-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/context-therapeutics-announces-positive-results-from-phase-1-ctim-76-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","CNTX","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643927739","title":"Context Therapeutics reports 29% response rate in Phase 1 trial of CTIM-76 for platinum-resistant ovarian cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2643927739","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643927739?lang=en_us&edition=fundamental","pubTime":"2026-06-15 18:30","pubTimestamp":1781519433,"startTime":"0","endTime":"0","summary":"Context Therapeutics reported positive interim Phase 1 results for CTIM-76 in late-line platinum-resistant ovarian cancer; results have now been presented.Patients showed meaningful tumor shrinkage in a heavily pretreated setting, supporting continued development of the program.Safety looked manageable, with immune-related reactions generally mild and concentrated early in treatment.The FDA granted Fast Track designation for CTIM-76 in this ovarian cancer setting, strengthening the regulatory path.The dosing strategy is set to shift toward less frequent administration in 2H 2026, with expansion decisions targeted for 2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL5cVr0n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK4585","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4112","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014039.USD","SG9999014013.SGD","LU2210150020.SGD","BK4588","IE00BKPKM429.USD","LU0314104364.USD","BK4007","CNTX","NDAQ","LU2095319765.USD","SG9999014021.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643720022","title":"Context Therapeutics Announces Positive Interim Efficacy and Safety Results From Ongoing Phase 1 Clinical Trial for Ctim-76","url":"https://stock-news.laohu8.com/highlight/detail?id=2643720022","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643720022?lang=en_us&edition=fundamental","pubTime":"2026-06-15 18:30","pubTimestamp":1781519400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUAP1TRG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643277363","title":"Context Therapeutics - Ctim-76 Granted FDA Fast Track Designation in Proc","url":"https://stock-news.laohu8.com/highlight/detail?id=2643277363","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643277363?lang=en_us&edition=fundamental","pubTime":"2026-06-15 18:30","pubTimestamp":1781519400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUAP1TRG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643277359","title":"Context Therapeutics - Reports 29% Confirmed Overall Response Rate in Proc Patients With Median 7 Prior Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2643277359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643277359?lang=en_us&edition=fundamental","pubTime":"2026-06-15 18:30","pubTimestamp":1781519400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUAP1TRG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642828497","title":"Context Therapeutics grants new hire stock options for 146,000 shares at USD 1.71 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2642828497","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642828497?lang=en_us&edition=fundamental","pubTime":"2026-06-10 04:11","pubTimestamp":1781035872,"startTime":"0","endTime":"0","summary":"Context Therapeutics granted a non-qualified stock option for 146,000 shares to a new employee as an inducement award.Options were issued on June 8, 2026 with an exercise price of USD 1.71 per share.The award has a 10-year term with four-year vesting, including a one-year cliff then monthly vesting.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDLc1wwW3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210149790.SGD","NDAQ","IE00BN0W2W23.USD","SG9999014005.SGD","SG9999014039.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2095319765.USD","IE00BN0W2T93.GBP","SG9999014021.USD","BK4007","SG9999014013.SGD","BK4585","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","BK4588","IE00B3QW5Z07.USD","LU2210150020.SGD","LU0314104364.USD","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642949789","title":"Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642949789","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642949789?lang=en_us&edition=fundamental","pubTime":"2026-06-10 04:10","pubTimestamp":1781035857,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nTUA71X8G9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642792497","title":"Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642792497","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642792497?lang=en_us&edition=fundamental","pubTime":"2026-06-10 04:10","pubTimestamp":1781035800,"startTime":"0","endTime":"0","summary":"PHILADELPHIA, June  09, 2026  (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/09/3309326/0/en/Context-Therapeutics-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","BK4539","CNTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638029425","title":"Context Therapeutics grants new hire stock options for 146,000 shares at USD 2.63 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2638029425","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638029425?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:31","pubTimestamp":1779881471,"startTime":"0","endTime":"0","summary":"Context Therapeutics granted a non-qualified stock option for 146,000 common shares to a new employee as an inducement award.Exercise price set at USD 2.63 per share, based on the Nasdaq close on May 26, 2026.Options run for 10 years; 25% vests after one year, with the balance vesting monthly over the next 36 months.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL1BRjp3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","SG9999014039.USD","CNTX","BK4112","BK4588","SG9999014005.SGD","LU2095319765.USD","LU2210150020.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00BN0W2V16.EUR","BK4585","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","NDAQ","SG9999014013.SGD","SG9999014021.USD","BK4007","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636856533","title":"Context Therapeutics Decline Means Insider Profits Down To US$237k","url":"https://stock-news.laohu8.com/highlight/detail?id=2636856533","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636856533?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:36","pubTimestamp":1779190586,"startTime":"0","endTime":"0","summary":"Insiders who bought Context Therapeutics Inc. ( NASDAQ:CNTX ) in the last 12 months may probably not pay attention to...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cntx/context-therapeutics/news/context-therapeutics-decline-means-insider-profits-down-to-u","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cntx/context-therapeutics/news/context-therapeutics-decline-means-insider-profits-down-to-u","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4539","BK4139","LENZ","CNTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636180839","title":"Analysts’ Top Healthcare Picks: Boston Scientific (BSX), Context Therapeutics (CNTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636180839","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636180839?lang=en_us&edition=fundamental","pubTime":"2026-05-19 16:41","pubTimestamp":1779180077,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Boston Scientific (BSX), Context Therapeutics (CNTX)...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-boston-scientific-bsx-context-therapeutics-cntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-boston-scientific-bsx-context-therapeutics-cntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0048584097.USD","LU1720051108.HKD","LU2491050071.SGD","LU2362541513.USD","BSX","LU2491050154.USD","LU2506952170.USD","LU0187121727.USD","LU1548497426.USD","LU1989772840.SGD","XBI","LU0077335932.USD","LU1989772923.USD","SG9999001176.SGD","LU2357305700.SGD","BK4581","LU2491049909.HKD","LU0128526141.USD","LU1057294990.SGD","LU0432979614.USD","LU0882574055.USD","LU1366192091.USD","LU1720051017.SGD","XLV","LU2506951958.HKD","LU0823417737.USD","LU0345769631.USD","LU0251132253.USD","LU1791710582.SGD","LU0823416689.USD","IE00B2B36J28.USD","LU2506952097.USD","LU0267386448.USD","LU0823417653.USD","LU1989764748.USD","BK4007","LU0238689110.USD","LU1153585028.USD","BK4504","HCSG","LABU","LU0225283273.USD","LU0029874061.USD","LU2324357040.USD","LU2362541273.HKD","LU2112291526.USD","SG9999001176.USD","LU0011850046.USD","CNTX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636933020","title":"Context Therapeutics Secures Full Rights to Antibody Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2636933020","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636933020?lang=en_us&edition=fundamental","pubTime":"2026-05-18 19:20","pubTimestamp":1779103242,"startTime":"0","endTime":"0","summary":"Context Therapeutics ( ($CNTX) ) has issued an update. On May 14, 2026, Context Therapeutics amended its 2024 exclusive license agreement with BioA...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-secures-full-rights-to-antibody-assets?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-secures-full-rights-to-antibody-assets?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","CNTX","BK4539","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636271790","title":"Context Therapeutics enters license agreement amendment with BioAtla","url":"https://stock-news.laohu8.com/highlight/detail?id=2636271790","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636271790?lang=en_us&edition=fundamental","pubTime":"2026-05-18 18:54","pubTimestamp":1779101659,"startTime":"0","endTime":"0","summary":"Context Therapeutics (CNTX) announced the amendment of the company’s exclusive license agreement, dated September 23, 2024, with BioAtla (BCAB). Th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/context-therapeutics-enters-license-agreement-amendment-with-bioatla-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/context-therapeutics-enters-license-agreement-amendment-with-bioatla-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAB","LENZ","BK4007","BK4539","CNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636700022","title":"Context Therapeutics pays USD 6.5 million to buy out CT-202 milestones, royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2636700022","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636700022?lang=en_us&edition=fundamental","pubTime":"2026-05-18 18:47","pubTimestamp":1779101229,"startTime":"0","endTime":"0","summary":"Context Therapeutics amended its exclusive license agreement with BioAtla for CT-202, eliminating all future milestone and royalty obligations.The amendment requires a USD 4.5 million upfront payment, with a final USD 2 million payment due by Aug. 1, 2026, in exchange for a fully paid-up, non-terminable license.Phase 1 initiation for the CT-202 trial is expected in Q3 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief on May 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL1Kk0v1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","BCAB","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636227490","title":"Context Therapeutics Enters Into License Agreement Amendment With Bioatla for Ct-202","url":"https://stock-news.laohu8.com/highlight/detail?id=2636227490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636227490?lang=en_us&edition=fundamental","pubTime":"2026-05-18 18:45","pubTimestamp":1779101100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUABZWSH3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNTX","BK4139","BK4007","BCAB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.contexttherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0821},{"period":"1month","weight":-0.8054},{"period":"3month","weight":-0.7761},{"period":"6month","weight":-0.4867},{"period":"1year","weight":-0.1095},{"period":"ytd","weight":-0.6054}],"compareEarnings":[{"period":"1week","weight":-0.0238},{"period":"1month","weight":-0.0286},{"period":"3month","weight":0.1497},{"period":"6month","weight":0.056},{"period":"1year","weight":0.1914},{"period":"ytd","weight":0.069}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.188281},{"month":2,"riseRate":0.2,"avgChangeRate":-0.080088},{"month":3,"riseRate":0.6,"avgChangeRate":-0.010229},{"month":4,"riseRate":0.4,"avgChangeRate":-0.001309},{"month":5,"riseRate":0.8,"avgChangeRate":0.277604},{"month":6,"riseRate":0.6,"avgChangeRate":0.027395},{"month":7,"riseRate":0.5,"avgChangeRate":-0.057392},{"month":8,"riseRate":0.75,"avgChangeRate":0.057821},{"month":9,"riseRate":0.5,"avgChangeRate":0.000078},{"month":10,"riseRate":0.75,"avgChangeRate":0.018618},{"month":11,"riseRate":0.6,"avgChangeRate":-0.036732},{"month":12,"riseRate":0.4,"avgChangeRate":-0.161685}],"exchange":"NASDAQ","name":"Context Therapeutics Inc.","nameEN":"Context Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Context Therapeutics Inc.(CNTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Context Therapeutics Inc.(CNTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Context Therapeutics Inc.,CNTX,Context Therapeutics Inc.股票,Context Therapeutics Inc.股票老虎,Context Therapeutics Inc.股票老虎国际,Context Therapeutics Inc.行情,Context Therapeutics Inc.股票行情,Context Therapeutics Inc.股价,Context Therapeutics Inc.股市,Context Therapeutics Inc.股票价格,Context Therapeutics Inc.股票交易,Context Therapeutics Inc.股票购买,Context Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Context Therapeutics Inc.(CNTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Context Therapeutics Inc.(CNTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}